AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $2.52M | $3.36M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $1.00K |
| Gross Profit | N/A | N/A | N/A | N/A | $2.52M | $3.36M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 99.97% |
| Operating Expenses | $-72.98M | $348.09M | $48.43M | $65.85M | $18.91M | $57.32M |
| Operating Income | $72.98M | $-348.09M | $-48.43M | $-65.85M | $-16.39M | $-53.97M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | -650.83% | -1607.57% |
| Net Income | $42.01M | $-384.63M | $-52.56M | $-55.64M | $-32.91M | $172.92M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | -1307.11% | 5151.03% |
| EPS (Basic) | $77.74 | $-4.99 | $-27.25 | $-31.73 | $-547.60 | $1495.96 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |